Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Clin Pharmacol ; 88(1): 214-225, 2022 01.
Article in English | MEDLINE | ID: mdl-34155670

ABSTRACT

AIMS: Hypothyroxinaemia could be easily neglected if attention is paid only to patients with elevated thyroid-stimulating hormone. We aimed to assess the association between mirtazapine use and hypothyroxinaemia in patients affected by major depressive disorder. METHODS: We conducted a retrospective cohort study in the Second Affiliated Hospital of Xinxiang Medical University between January 2016 and December 2018. Patients affected by major depression disorder and admitted to the hospital for treatment during the study period and who had thyroid tests at admission and after treatment were included. Mirtazapine use during hospitalization was the exposure measure and newly developed hypothyroxinaemia was as the primary outcome and structure parameters of thyroid homeostasis were the secondary outcomes of this study. Log-binomial model was used to estimate the association between mirtazapine use and hypothyroxinaemia, after adjusting for potential confounding factors. RESULTS: A total of 220 eligible patients were included in the final analysis. The incidence of hypothyroxinaemia in patients who used mirtazapine was higher (37.5%) than those patients who did not use (19.7%). The relative risk of developing hypothyroxinaemia was 1.70 (95% confidence interval: 1.21-2.43) for mirtazapine use, after adjusting for confounding factors. The degree of reduction in thyroid feedback quantile-based index in mirtazapine group was significantly greater than that in nonmirtazapine group. CONCLUSION: Mirtazapine use was associated with the increased risk of developing hypothyroxinaemia. The underlying mechanism may be involved the changed central set point of thyroid homeostasis, in which pituitary was in a possibly impaired sensitivity to the lower level of thyroid hormones.


Subject(s)
Depressive Disorder, Major , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/epidemiology , Humans , Incidence , Mirtazapine/adverse effects , Retrospective Studies
2.
Nanomaterials (Basel) ; 11(10)2021 Oct 08.
Article in English | MEDLINE | ID: mdl-34685086

ABSTRACT

With the energy crisis and environmental pollution becoming more and more serious, it is urgent to develop renewable and clean energy. Hydrogen production from electrolyzed water is of great significance to solve the energy crisis and environmental problems in the future. Recently, layered double hydroxides (LDHs) materials have been widely studied in the electrocatalysis field, due to their unique layered structure, tunable metal species and highly dispersed active sites. Moreover, the LDHs supporting noble metal catalysts obtained through the topotactic transformation of LDHs precursors significantly reduce the energy barrier of electrolyzing water, showing remarkable catalytic activity, good conductivity and excellent durability. In this review, we give an overview of recent advances on LDHs supporting noble metal catalysts, from a brief introduction, to their preparation and modification methods, to an overview of their application in the electrocatalysis field, as well as the challenges and outlooks in this promising field on the basis of current development.

3.
Neuroscience ; 475: 83-92, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34534635

ABSTRACT

Network oscillations at γ frequency band (30-80 Hz), generated by the interaction between inhibitory interneurons and excitatory neurons, have been proposed to be associated with higher brain functions such as learning and memory. Dopamine (DA), one of the major CNS transmitters, modulates hippocampal γ oscillations but the intracellular mechanisms involved remain elusive. In this study, we recorded kainate-induced γ oscillations in the CA3 area of rat hippocampal slices, and found that DA strongly enhanced γ power, which was largely blocked by dopamine receptor 1 (DR1) antagonist SCH23390, receptor tyrosine kinase (RTK) inhibitor UNC569 and ERK inhibitor U0126, partially blocked by D2/3R antagonist raclopride, PKA inhibitor H89 and PI3K inhibitor wortmannin, but not affected by AKT inhibitor TCBN or NMDAR antagonist D-AP5. Our results indicate that DA-mediated γ enhancement is involved in the activation of signaling pathway of DR1/2-RTK-ERK. Our data demonstrate a strong, rapid modulation of DA on hippocampal γ oscillations and provide a new insight into cellular mechanisms of DA-mediated γ oscillations.


Subject(s)
Dopamine , Phosphatidylinositol 3-Kinases , Animals , Hippocampus , Kainic Acid , Neurons , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...